半夏白术天麻汤治疗椎基底动脉供血不足性眩晕的系统评价与Meta分析
该系统评价纳入27项RCT共2796例患者,评估半夏白术天麻汤(BBTD)治疗椎基底动脉供血不足性眩晕的疗效。与抗眩晕药相比,BBTD单用临床疗效略有改善(RR 1.09,95%CI 1.01-1.18,p=0.03);BBTD联合抗眩晕药显著提高临床疗效(RR 1.20,95%CI 1.16-1.24,p<0.00001)并加快椎基底动脉血流速度。但试验数量有限且方法学质量低,疗效与安全性尚不确定。
要点
- BBTD联合抗眩晕药可显著提高椎基底动脉供血不足性眩晕的临床疗效。
- 联合治疗可加快左、右椎动脉及基底动脉的血流速度。
- BBTD单用疗效有限,且安全性证据不足,需高质量RCT验证。
核心结论
- 当前证据表明BBTD联合抗眩晕药治疗椎基底动脉供血不足性眩晕有效。
- 由于试验数量有限和方法学质量低,BBTD单用的疗效与安全性尚不确定。
研究设计与样本
- 系统评价与Meta分析,检索7个电子数据库截至2016年7月发表的随机对照试验。
- 共纳入27项研究,合计2796例患者,比较BBTD、抗眩晕药及两者联合。
主要发现
- 与抗眩晕药相比,BBTD单用对临床疗效有轻微改善(n=350;RR 1.09;95%CI 1.01-1.18;p=0.03;I2=0%)。
- BBTD联合抗眩晕药显著改善临床疗效(n=2446;RR 1.20;95%CI 1.16-1.24;p<0.00001;I2=0%)。
- 联合治疗加快左椎动脉血流速度(n=1444;WMD 5.21cm/s;95%CI 3.72-6.70cm/s;p<0.00001;I2=91%)。
- 联合治疗加快右椎动脉血流速度(n=1444;WMD 5.45cm/s;95%CI 4.02-6.88cm/s;p<0.00001;I2=89%)。
- 联合治疗加快基底动脉血流速度(n=1872;WMD 5.20cm/s;95%CI 3.86-6.54cm/s;p<0.00001;I2=90%)。
关键数值与推荐
- 临床疗效为结局指标之一,采用RR及95%CI汇总。
- 椎基底动脉血流速度经颅多普勒(TCD)测量,采用WMD及95%CI汇总。
- 不良反应在6项研究中提及。
临床怎么用
- 对于椎基底动脉供血不足性眩晕,可考虑BBTD联合抗眩晕药以改善临床疗效和椎基底动脉血流速度。
- BBTD单用疗效证据较弱,应结合患者具体情况谨慎使用。
局限性
- 纳入试验数量有限且方法学质量低,可能影响结论可靠性。
- 不良反应仅6项研究提及,安全性数据不足。
- 部分血流速度分析异质性较高(I2最高达91%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Banxia Baizhu Tianma Decoction (BBTD) is widely used to treat vertebrobasilar insufficiency vertigo (VBIV) in China, but its efficacy remains largely unexplored. We systemically summarized relevant evidence from randomized controlled trials (RCTs) to assess the therapeutic effect of BBTD. METHODS: Seven electronic databases were searched for relevant electronic studies published before July 2016. We evaluated RCTs that compared BBTD, anti-vertigo drugs and a combination of BBTD and anti-vertigo drugs. We performed a meta-analysis in accordance with the Cochrane Collaboration criteria. The outcomes were clinical efficacy (CE), blood flow velocity of the vertebrobasilar artery by transcranial Doppler (TCD), and adverse effects. RESULTS: Twenty-seven studies with a total of 2796 patients were identified. Compared with anti-vertigo drugs, BBTD showed slight effects on CE (n=350; RR, 1.09; 95% CI, 1.01-1.18; p=0.03; I2=0%); however, BBTD plus anti-vertigo drugs (BPAD) significantly improved the clinical efficacy (n=2446; RR, 1.20; 95% CI, 1.16-1.24; p<0.00001; I2=0%) and accelerated the blood flow velocity of the left vertebral artery (LVA) (n=1444; WMD, 5.21cm/s; 95% CI, 3.72-6.70cm/s; p<0.00001; I2=91%), the blood flow velocity of the right vertebral artery (RVA) (n=1444; WMD, 5.45cm/s; 95% CI, 4.02-6.88cm/s; p<0.00001; I2=89%), and the blood flow velocity of the basilar artery (BA) (n=1872; WMD, 5.20cm/s; 95% CI, 3.86-6.54cm/s; p<0.00001; I2=90%). Adverse effects were mentioned in six studies. CONCLUSIONS: The current evidence indicates that BPAD is effective for the treatment of VBIV, but the efficacy and safety of BBTD is uncertain because of the limited number of trials and low methodological quality. Hence, high-quality and adequately powered RCTs are warranted.
引用
- Guo Z, Su Z, Wang Z, et al. The effect of chinese herbal medicine Banxia Baizhu Tianma Decoction for the treatment of vertebrobasilar insufficiency vertigo: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2017. PMID: 28434468. doi:10.1016/j.ctim.2017.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。